These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
689 related articles for article (PubMed ID: 24259661)
1. Dabrafenib therapy for advanced melanoma. Trinh VA; Davis JE; Anderson JE; Kim KB Ann Pharmacother; 2014 Apr; 48(4):519-29. PubMed ID: 24259661 [TBL] [Abstract][Full Text] [Related]
2. Controversies in the management of advanced melanoma: "gray" areas amid the "black and blue". Jarkowski A; Norris L; Trinh VA Ann Pharmacother; 2014 Nov; 48(11):1456-68. PubMed ID: 25056920 [TBL] [Abstract][Full Text] [Related]
3. Dabrafenib and its potential for the treatment of metastatic melanoma. Menzies AM; Long GV; Murali R Drug Des Devel Ther; 2012; 6():391-405. PubMed ID: 23251089 [TBL] [Abstract][Full Text] [Related]
4. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819 [TBL] [Abstract][Full Text] [Related]
5. Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies. Gibney GT; Zager JS Expert Opin Drug Metab Toxicol; 2013 Jul; 9(7):893-9. PubMed ID: 23621583 [TBL] [Abstract][Full Text] [Related]
6. Dabrafenib for Treating Unresectable, Advanced or Metastatic BRAF V600 Mutation-Positive Melanoma: An Evidence Review Group Perspective. Fleeman N; Bagust A; Beale S; Boland A; Dickson R; Dwan K; Richardson M; Dundar Y; Davis H; Banks L Pharmacoeconomics; 2015 Sep; 33(9):893-904. PubMed ID: 25906420 [TBL] [Abstract][Full Text] [Related]
7. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma. Ravnan MC; Matalka MS Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884 [TBL] [Abstract][Full Text] [Related]
8. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma. Menzies AM; Long GV Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796 [TBL] [Abstract][Full Text] [Related]
9. Dabrafenib in the treatment of advanced melanoma. Medina T; Amaria MN; Jimeno A Drugs Today (Barc); 2013 Jun; 49(6):377-85. PubMed ID: 23807941 [TBL] [Abstract][Full Text] [Related]
10. Dabrafenib plus Trametinib: a Review in Advanced Melanoma with a BRAF (V600) Mutation. Dhillon S Target Oncol; 2016 Jun; 11(3):417-28. PubMed ID: 27246822 [TBL] [Abstract][Full Text] [Related]
11. Improved overall survival in melanoma with combined dabrafenib and trametinib. Robert C; Karaszewska B; Schachter J; Rutkowski P; Mackiewicz A; Stroiakovski D; Lichinitser M; Dummer R; Grange F; Mortier L; Chiarion-Sileni V; Drucis K; Krajsova I; Hauschild A; Lorigan P; Wolter P; Long GV; Flaherty K; Nathan P; Ribas A; Martin AM; Sun P; Crist W; Legos J; Rubin SD; Little SM; Schadendorf D N Engl J Med; 2015 Jan; 372(1):30-9. PubMed ID: 25399551 [TBL] [Abstract][Full Text] [Related]
12. Vemurafenib for the treatment of BRAF mutant metastatic melanoma. Martin-Liberal J; Larkin J Future Oncol; 2015; 11(4):579-89. PubMed ID: 25686114 [TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of dabrafenib as a first-line treatment in patients with BRAF V600 mutation-positive unresectable or metastatic melanoma in Canada. Delea TE; Amdahl J; Wang A; Amonkar MM; Thabane M Pharmacoeconomics; 2015 Apr; 33(4):367-80. PubMed ID: 25488880 [TBL] [Abstract][Full Text] [Related]
14. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. Ascierto PA; Minor D; Ribas A; Lebbe C; O'Hagan A; Arya N; Guckert M; Schadendorf D; Kefford RF; Grob JJ; Hamid O; Amaravadi R; Simeone E; Wilhelm T; Kim KB; Long GV; Martin AM; Mazumdar J; Goodman VL; Trefzer U J Clin Oncol; 2013 Sep; 31(26):3205-11. PubMed ID: 23918947 [TBL] [Abstract][Full Text] [Related]
15. Vemurafenib (PLX4032): an orally available inhibitor of mutated BRAF for the treatment of metastatic melanoma. Heakal Y; Kester M; Savage S Ann Pharmacother; 2011 Nov; 45(11):1399-405. PubMed ID: 22028422 [TBL] [Abstract][Full Text] [Related]
16. Dabrafenib in an elderly patient with metastatic melanoma and BRAF V600R mutation: a case report. Casadevall D; Vidal J; Gallardo F; Zuccarino F; Arumí-Uría M; Dalmases A; Bellosillo B; Montagut C J Med Case Rep; 2016 Jun; 10(1):158. PubMed ID: 27255157 [TBL] [Abstract][Full Text] [Related]
17. Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma. Carlos G; Anforth R; Clements A; Menzies AM; Carlino MS; Chou S; Fernandez-Peñas P JAMA Dermatol; 2015 Oct; 151(10):1103-9. PubMed ID: 26200476 [TBL] [Abstract][Full Text] [Related]
18. Leukocyte count restoration under dabrafenib treatment in a melanoma patient with vemurafenib-induced leukopenia: case report. Orouji E; Ziegler B; Umansky V; Gebhardt C; Utikal J Medicine (Baltimore); 2014 Dec; 93(28):e161. PubMed ID: 25526431 [TBL] [Abstract][Full Text] [Related]
19. New RAF kinase inhibitors in cancer therapy. Martin-Liberal J; Larkin J Expert Opin Pharmacother; 2014 Jun; 15(9):1235-45. PubMed ID: 24766074 [TBL] [Abstract][Full Text] [Related]
20. Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma. Spagnolo F; Ghiorzo P; Queirolo P Oncotarget; 2014 Nov; 5(21):10206-21. PubMed ID: 25344914 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]